Cancer Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174
Gilteritinib was well tolerated in a phase I/II dose-escalation and dose-expansion study.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου